Liking some longer-term call options on $PRVB out to Oct 20 (strikes around $20). Company has laid out a nice plan for teplizumab to get on the market in the next year for treatment/prevention of Type 1 #diabetes in high-risk population. Potentially huge market. #stocks #biotech